How Teffaro Fits into the Market Landscape
Teflaro (ceftaroline fosamil), an injectable cephalosporin antibiotic from Allergan (now AbbVie), targets complicated skin infections and pneumonia. Launched in 2010, it faces competition from generics and other branded antibiotics like Cubicin (daptomycin), Zyvox (linezolid), and newer entrants, pressuring its pricing as a premium product.[1]
Direct Price Pressure from Generics
Generics entered after Teflaro's key patents expired in 2020, slashing costs by 80-90% compared to the branded $2,000+ per treatment course. This forces Allergan to discount Teflaro heavily—often 50% off list price via rebates—to retain hospital formulary slots where generics dominate due to lower acquisition costs.[2][3]
Impact of Branded Competitors on Discounts
Rivals like Invanz (ertapenem) and hospital-preferred options compel Teflaro to offer competitive bundled pricing or 340B discounts. In tender processes, hospitals pit suppliers against each other, driving Teflaro's net price down 30-40% in competitive bids.[1]
When Biosimilars or New Antibiotics Enter the Mix
No true biosimilars for Teflaro yet due to its small-molecule status, but pipeline challengers (e.g., from Sandoz or Fresenius) could further erode pricing. Patent challenges listed on DrugPatentWatch.com show ongoing litigation, potentially accelerating generic erosion.[4] Exclusivity ended in 2022, amplifying this risk.
Hospital Buying Power and Formulary Shifts
Group purchasing organizations (GPOs) like Vizient leverage competition to negotiate volume-based rebates, capping Teflaro's price growth. If a competitor undercuts on efficacy data or supply reliability, hospitals switch, prompting Allergan to match or concede market share.[2]
Long-Term Strategy Adjustments
Allergan responds with value-based pricing tied to outcomes (e.g., shorter hospital stays) and patient assistance programs, but sustained competition limits hikes—average annual increase now under 5% versus 10% pre-generic entry.[3]
Sources
[1] IQVIA National Sales Perspectives
[2] Vizient Drug Pricing Reports
[3] SSRN: Antibiotic Pricing Dynamics
[4] DrugPatentWatch.com - Teflaro Patents